Nice to Know

In this section Cosmo will publish non-price sensitive news including information about upcoming events or announcements.

20/06/2013 European Mediscience Awards

Cosmo Pharmaceuticals S.p.A. was awarded the European Mediscience Award for best technology at a celebratory dinner on Thursday June 20, 2013 in London. The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognising achievements in the life sciences industry.

11/01/2012 Country Representative European Business Awards 2011 – EBA Case Study

08/06/2011 Full article from British Journal of Dermatology

Cortexolone 17α-propionate 1% cream, a new potent anti-androgen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus placebo and tretinoin (Retin-A® 0.05% cream) – (Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G).

24/03/2011 Abstract from British Journal of Dermatology

Cortexolone 17α-propionate 1% cream, a new potent anti-androgen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus placebo and tretinoin (Retin-A® 0.05% cream) – (Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G).

13/12/2010 Abstract from Antimicrob Agents Chemother

In vitro Activity and Single-Step Mutational Analysis of Rifamycin SV Tested Against Enteropathogens Associated With Travelers' Diarrhea and Clostridium Difficile (Farrell DJ, Putnam SD, Biedenbach DJ, Moro L, Bozzella R, Celasco G, Jones RN).

25/03/2010 Santarus announces completion of enrollment in U.S. Phase III clinical study for Budesonide MMX

30/12/2009 Santarus Submits IND For Phase III Clinical Testing Of Rifamycin SV MMX In Travelers' Diarrhea

03/06/2009 Poster abstracts presented at the Digestive Disease Week (DDW)

05/05/2008 Inclusion of Cosmo in Swiss Performance Index (SPI)

Cosmo has received confirmation from SWX Swiss Exchange that the company's shares will be included in the Swiss Performance Index (SPI) as of 6 May, 2008. As of this day, the SPI will be open to all foreign domiciled companies that have a primary listing on SWX, subject to certain free-float.

04/10/2007 Market Making Agreement

In order to facilitate the daily trading of our shares on the SWX we have entered into a market making agreement with a well know bank that has a seat at the SWX.

25/04/2007 LIALDA™ (mesalamine)

LIALDA, the only once-daily oral formulation of mesalamine and approved by the FDA on January 16, 2007 became available to patients in the US on March 19, 2007.

Delivered by Investis – link to website (opens in a new window)